IDEXX Laboratories Stock News

Boosted by solid growth and clear demand among the best mutual funds, Idexx stock has blasted out into buy range.

IDEXX Laboratories' (IDXX) recent jump has investors questioning whether it's still the best bet—or if a stronger opportunity exists elsewhere. A closer look at its key competitor suggests there may be a clearer winner.

The steep increase in pet healthcare costs have doubled over the past five years, according to NPR.

Baron Asset Fund underperformed for a second consecutive quarter as U.S. equities continued their strong rally from the market lows reached on April 8. From a sector perspective, stock selection in IT and Communication Services was responsible for about three-quarters of the underperformance in the period. Stock selection in Consumer Discretionary, Financials, and Industrials hampered relative ...

No single month beats November for S&P 500 stock market performance. And a handful of stocks are already taking off.

IDEXX Laboratories (IDXX) continues to outperform the S&P 500, driven by strong recurring revenue and a robust customer ecosystem. IDXX delivered a double beat in Q3, with revenue up 13% and EPS up 21%, alongside expanding margins and reduced debt. International growth, new product launches like InVueDx, and ongoing share buybacks are key catalysts for future performance.

IDEXX Laboratories (NASDAQ: IDXX) extended its streak of earnings beats this morning, reporting Q3 results that topped both EPS and revenue expectations while raising full-year guidance.

It notched a beat-and-raise third quarter. It cited innovation and increased customer take-up as reasons for the solid growth it posted during the frame.